Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Cash & Current Investments: 2023-2024

Historic Cash & Current Investments for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to $350.8 million.

  • Zenas BioPharma's Cash & Current Investments rose 32.43% to $476.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 176.05%. This contributed to the annual value of $350.8 million for FY2024, which is 516.93% up from last year.
  • As of FY2024, Zenas BioPharma's Cash & Current Investments stood at $350.8 million, which was up 516.93% from $56.9 million recorded in FY2023.
  • Zenas BioPharma's 5-year Cash & Current Investments high stood at $350.8 million for FY2024, and its period low was $56.9 million during FY2023.
  • Over the past 2 years, Zenas BioPharma's median Cash & Current Investments value was $203.8 million (recorded in 2023), while the average stood at $203.8 million.
  • Data for Zenas BioPharma's Cash & Current Investments shows a peak YoY skyrocketed of 516.93% (in 2024) over the last 5 years.
  • Zenas BioPharma's Cash & Current Investments (Yearly) stood at $56.9 million in 2023, then skyrocketed by 516.93% to $350.8 million in 2024.